What does deuterated coxitinib treat?

Deuterated colexitinib is mainly used to treat adult patients with moderate to severe plaque psoriasis who are suitable for systemic treatment or phototherapy. Psoriasis, commonly known as "psoriasis", is a common chronic, relapsing, inflammatory, and systemic disease. It not only affects the skin, but may also cause damage to joints and nails, seriously affecting the patient's quality of life.

Deuterated colexitinib is an oral inhibitor of tyrosine kinase 2 (TYK2). It exerts a therapeutic effect by selectively binding to the regulatory domain of TYK2 and inhibiting its downstream functions. Specifically, it can block the signaling of multiple cytokines involved in the pathogenesis of psoriasis, such as interleukin (IL)-23 (IL), IL-12 and type I interferon (IFN), etc.

In clinical trials, deuterated colexitinib has demonstrated significant therapeutic effects. For example, in a pivotal study, a certain proportion of patients who received the drug achieved PASI 75 (i.e., skin lesions improved by more than 75%) after 16 weeks, which was much higher than the placebo group.

In addition to its remarkable efficacy, the safety and tolerability of deuterated colexitinib have also been verified. In clinical trials, although some patients experienced mild adverse reactions, such as upper respiratory tract infection, increased blood creatine kinase, etc., the incidence of serious adverse reactions was relatively low. This makes deuterated colexitinib a relatively safe and effective treatment option.

As the only approved TYK2 inhibitor in the world, the launch of deuterated colexitinib provides a new treatment option for psoriasis patients. Its unique efficacy and safety have been widely recognized. It has not only been approved for marketing in the United States, but has also been gradually used around the world.